Elizabeth Swisher, MDUniversity of WashingtonSeattle, WA Optimizing genetic testing uptake and outcomes for hereditary ovarian cancer risk As genetic testing for cancer risk becomes increasingly accessible, the goal of eradicating hereditary ovarian cancer through comprehensive genetic testing and effective prevention is tantalizingly close. However, several large studies have revealed that a large minority of people […]
Read More
Barbara Norquist, MDUniversity of Washington2013 Skacel Family Scholar Genes Contributing to Hereditary Ovarian Cancer in BRCA1/2 Wildtype Families Nearly a quarter of ovarian cancer cases may be caused by inherited mutations, with a significant portion caused by mutations in genes other than BRCA1 and BRCA2 (BRCA1/2). Next generation sequencing techniques have made it possible to […]
Read More
Alexandra Snyder Charen, MDSloan-Kettering Institute for Cancer Researchr Chemotherapy, Somatic Mutations, and Neoantigens in Ovarian Cancer Immunotherapy is a new treatment that boosts a patient’s immune system to attack ovarian cancer cells. Dr. Synder Charen’s lab has already shown in melanoma that when a tumor has a large number of genetic abnormalities (mutations), the immune […]
Read More
Benjamin Izar, MD, PhDDana-Farber Cancer Institute Single-cell transcriptome analysis of treatment-resistant ovarian cancer and new strategies for drug discovery Dr. Izar will be studying in fine detail the molecular changes that take place from the time that ovarian cancer cells respond to platinum chemotherapy to when they become resistant. He will employ an innovative genetic […]
Read More
Elizabeth Harmon Stover, MD, PhDDana-Farber Cancer Institute Genomic analysis of plasma cell-free tumor DNA to evaluate clinical mechanisms of drug resistance in ovarian cancer Many ovarian cancers are able to resist drug treatment and therefore recur after months or years, posing a major challenge for clinicians and researchers. Currently research of resistant tumors is limited […]
Read More
Adam Karpf, PhDUniversity of Nebraska Medical Center2018 Kirwin-Hinton Bridge Funding Award Rhno1 in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer (HGSOC) is the most common and deadly form of ovarian cancer, accounting for about 25,000 cases and 15,000 deaths in the United States every year. New and improved therapies are critically needed for HGSOC. […]
Read More
Kwong-Kwok Wong, PhDUniversity of Texas MD Anderson Cancer Center To investigate invasion determinants in low-grade ovarian serous cancer Low-grade ovarian serous carcinomas (OSCs) appear to be a continuum from borderline tumors, and is often resistance to chemotherapy. The possible progression from borderline tumor to low-grade OSC will involve the acquisition of the ability to invade […]
Read More
Terry Van Dyke, PhD and Vickie Bae-Jump, MD, PhDThe University of North Carolina at Chapel Hill A Pathway to Therapeutic Treatment and Early Detection of Ovarian Cancer This project will compare global gene expression patterns across human and a novel genetically engineered mouse model of epithelial ovarian cancer in order to identify relevant molecular pathways […]
Read More
Toshi Taniguchi, MD, PhDFred Hutchinson Cancer Research Center Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, […]
Read More
Mark Gavin, MD, PhDUniversity of Minnesota A genetic screen for epithelial ovarian cancer genes With over 80 genes and 200 transcripts implicated in the development of ovarian cancer, there are little similarities among ovarian cancer. It is the goal of this study to identify those genes that are singularly critical to the genesis of the […]
Read More